Exact Sciences has launched a hereditary cancer test in the United States called Riskguard, the company announced this week.

According to a release, the test provides an individualized patient report that includes gene-specific and familial risks using a simple blood or saliva sample for 10 common cancers: colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine.

“Riskguard is a genetic test that can help patients understand their risk of developing certain cancers to inform screening, treatment and risks to other family members,” Exact Sciences Senior Director of Medical Affairs Brandie Leach said in a statement. “We believe that helping people to identify their risks – and take informed actions to reduce those risks – is a crucial step to help eradicate cancer and the suffering it causes.”

The Riskguard test is a multi-cancer multigene panel that provides a report on variants in genes that are actionable and are included in an easy-to-understand report with potential care options to support treatment discussions.

Medicare and various commercial insurance plans cover the test.